PCa Commentary | Volume 161 – January 2022
This Commentary looks at bipolar androgen therapy (BAT) as a treatment option for metastatic castration-resistant prostate cancer (mCRPC).
Read MoreSeattle
PCa Commentary | Volume 160 – December 2021
Posted by Edward Weber, MD | Dec 2021
This Commentary looks at gene mutations in the BRCA Family and PARP inhibition therapy for advanced prostate cancer.
Read MorePCa Commentary | Volume 159 – November 2021
Posted by Edward Weber, MD | Nov 2021
This Commentary looks at the application of genomics to therapy selection for patients metastatic hormone-sensitive prostate cancer (mHSPC).
Read MorePCa Commentary | Volume 158 – October 2021
Posted by Edward Weber, MD | Oct 2021
This Commentary considers the benefits of therapy of the primary tumor in newly diagnosed mHSPC, especially as this patient population grows.
Read MorePCa Commentary | Volume 157 – September 2021
Posted by Edward Weber, MD | Sep 2021
This Commentary considers the increased incidence of and evolving treatment options for metastatic hormone-sensitive prostate cancer.
Read More